Donoghue Forlines’s ResMed RMD Stock Holding History

Donoghue Forlines’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,839	Closed	-$1.91M	–	244
2024 Q3	$1.91M	Buy	+7,839	New	+$1.75M	0.55%	38
2021 Q4	–	Sell	-3,429	Closed	-$904K	–	297
2021 Q3	$904K	Buy	3,429 +162	+5%	+$44.3K	0.18%	143
2021 Q2	$805K	Buy	+3,267	New	+$687K	0.15%	150

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Donoghue Forlines's RMD Position: Q4 2024 in Review

Donoghue Forlines sold out of ResMed (RMD) in Q4 2024, closing a stake of 7,839 shares — an estimated $1.91M sold.

Donoghue Forlines first reported a position in RMD in Q2 2021 and held it in 3 quarters. The position peaked at $1.91M in Q3 2024. 871 funds tracked by Wall St. Rank hold RMD as of Q4 2024.

Donoghue Forlines reported no remaining ResMed position as of Q4 2024 after selling out during the quarter.
Donoghue Forlines sold 7,839 ResMed shares in Q4 2024, an estimated $1.91M.
Donoghue Forlines first reported a position in ResMed in Q2 2021 and held it in 3 quarters.
Donoghue Forlines's ResMed position peaked at $1.91M in Q3 2024.
871 funds tracked by Wall St. Rank held ResMed as of Q4 2024.

Based on Donoghue Forlines's 13F filing for Q4 2024, filed 17 Jan 2025.